[ad_1] First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ — Akeso (9926.HK) published results from three investigator-initiated trials (IITs)…
Tag: ESMO
Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023 | BioSpace
[ad_1] — Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy — TransCon…
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer | BioSpace
[ad_1] PALO ALTO, Calif.–(BUSINESS WIRE)– Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may be used…
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023 | BioSpace
[ad_1] ROCKLAND, Mass.–(BUSINESS WIRE)– EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the…